Best of ESMO 2025 in JAPAN Live and On-Demand

解説【291O】DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel+ trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)

Best of ESMO 2025 in JAPAN Live and On-Demand

解説【291O】DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel+ trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)

この動画に関するお問い合わせ先

Best of ESMO 2025運営事務局 

株式会社サンプラネット メディカル事業部

E-mail:jsmo-seminar@sunpla-mcv.com

 

齋藤 亜由美

国立がん研究センター中央病院

略歴

0.13294982910156 秒